Granted Patent B2

US 12,202,804 · App. 17/746,410 · Granted Jan 21, 2025

Inventors: Didier Scherrer (Castelnau le Lez, FR); Jamal Tazi (Clapiers, FR)

Assignees: ABIVAX; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT CURIE; UNIVERSITE DE MONTPELLIER

C07D215/38A61K31/47A61K31/4709A61K31/497A61K31/5377C07D401/12C12Q1/6883G01N33/5023G01N33/5055C12Q2600/136C12Q2600/158C12Q2600/178

Abstract

Claims (76)

1. An in vitro or ex vivo method for screening a quinoline derivative, or a pharmaceutically acceptable salt thereof, presumed effective in treating and/or preventing an inflammatory disease, comprising:

a) providing an eukaryotic cell,

b) bringing into contact said cell with the quinoline derivative or the pharmaceutically acceptable salt thereof,

c) measuring an expression of miR-124 in said cell, and

d) selecting the quinoline derivative or the pharmaceutically acceptable salt thereof presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured in step c) is increased relatively to a reference value,

wherein the quinoline derivative is a compound of formula (I)

or a pharmaceutically acceptable salt thereof,

wherein:

Z is C or N,

V is C or N,

 means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z and forms respectively a pyridine, a pyridazine, a pyrimidine or a pyrazine group,

R independently represents a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a (C 1 -C 3 ) fluoroalkyl group, a (C 1 -C 3 ) fluoroalkoxy group, a (C 3 -C 6 ) cycloalkyl group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 4 ) alkoxy group, a phenoxy group, a —NR 1 —SO 2 —NR 1 R 2 group, a —NR 1 —SO 2 —R 1 group, a —NR 1 —C(═O)—R 1 group, a —NR 1 —C(═O)—NR 1 R 2 group, a —SO 2 —NR 1 R 2 group, a —SO 3 H group, a —O—SO 2 —OR 3 group, a —O—P(═O)—(OR 3 ) (OR 4 ) group, a —O—CH 2 —COOR 3 group and a (C 1 -C 3 ) alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group,

Q is N or O, provided that R″ does not exist when Q is O,

R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 ) alkyl group,

R 3 and R 4 independently represent a hydrogen atom, Li + , Na + , K + , N + (Ra) 4 or a benzyl group,

n is 1, 2 or 3,

n′ is 1, 2 or 3,

R′ independently represents a hydrogen atom or a group chosen among a (C 1 -C 3 ) alkyl group, a halogen atom, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl group, a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 ) fluoroalkyl group, a —O—P(═O)—(OR 3 ) (OR 4 ) group, a —CN group, a group of formula (IIa), and a group of formula (IIIa):

A is a covalent bond, an oxygen atom or NH,

B is a covalent bond or NH,

m is 1, 2, 3, 4 or 5,

p is 1, 2 or 3,

Ra and Rb independently represent a hydrogen atom, a (C 1 -C 5 ) alkyl group or a (C 3 -C 6 ) cycloalkyl group,

Ra and Rb can further form together with the nitrogen atom to which they are attached a saturated 5- or 6-membered heterocycle optionally containing a further heteroatom chosen among N, O and S, said heterocycle being optionally substituted by one or more Ra, provided that when R′ is a group of formula (IIa) or a group of formula (IIIa), n′ may be 2 or 3 only if other R′ groups are different from said group of formula (IIa) or said group of formula (IIIa), and

R″ is a hydrogen atom, a (C 1 -C 4 ) alkyl group or is a group of formula (IIa) as defined above.

2. The method according to claim 1 , wherein said eukaryotic cell is a Peripheral Blood Mononuclear Cell (PBMC).

3. The method according to claim 1 , wherein R″ is a hydrogen atom, a (C 1 -C 4 ) alkyl group or a group

wherein

m is 2 or 3 and

X 1 is O, CH 2 or N—CH 3 .

4. The method according to claim 1 , wherein R independently represents a hydrogen atom, a methyl group, a methoxy group, a trifluoromethyl group, a trifluoromethoxy group, an amino group, a halogen atom, a fluorine, chlorine atom, or a —O—P(═O)—(OR 3 ) (OR 4 ) group.

5. The method according to claim 1 , wherein R′ independently represents a hydrogen atom, a halogen atom, a fluorine, chlorine atom, an amino group, a methyl group, a —O—P(═O)—(OR 3 ) (OR 4 ) group or a group

wherein

A is O or NH,

m is 2 or 3 and

X 1 is O, CH 2 or N—CH 3 , provided that when R′ is such a group, n′ is 1 or 2, and when n′ is 2, the other R′ group is different from said group or alternatively R′ independently represents a hydrogen atom, a halogen atom, a fluorine, chlorine atom, a methyl group or a group

wherein

A is O or NH,

m is 2 and

X 1 is O, CH 2 or N—CH 3 , provided that when R′ is such a group, n′ is 1 or 2, and when n′ is 2, the other R′ group is different from said group.

6. The method according to claim 1 , wherein Q is N.

7. The method according to claim 1 , wherein formula (I) is selected from

wherein R, R′, R″, n and n′ are as defined in claim 1 .

8. An in vitro or ex vivo method for assessing and following the efficacy of a compound of formula (I)

or a pharmaceutically acceptable salt thereof

wherein:

Z is C or N,

V is C or N,

 means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, and forms respectively a pyridine, a pyridazine, a pyrimidine or a pyrazine group,

R independently represents a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a (C 1 -C 3 ) fluoroalkyl group, a (C 1 -C 3 ) fluoroalkoxy group, a (C 3 -C 6 ) cycloalkyl group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 4 ) alkoxy group, a phenoxy group, a —NR 1 —SO 2 —NR 1 R 2 group, a —NR 1 —SO 2 —R 1 group, a —NR 1 —C(═O)—R 1 group, a —NR 1 —C(═O)—NR 1 R 2 group, a —SO 2 —NR 1 R 2 group, a —SO 3 H group, a —O—SO 2 —OR 3 group, a —O—P(═O)—(OR 3 ) (OR 4 ) group, a —O—CH 2 —COOR 3 group and a (C 1 -C 3 ) alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group,

Q is N or O, provided that R″ does not exist when Q is O,

R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 ) alkyl group,

R 3 and R 4 independently represent a hydrogen atom, Li + , Na + , K + , N + (Ra) 4 or a benzyl group,

n is 1, 2 or 3,

n′ is 1, 2 or 3,

R′ independently represents a hydrogen atom or a group chosen among a (C 1 -C 3 ) alkyl group, a halogen atom, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl group, a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 ) fluoroalkyl group, a —O—P(═O)—(OR 3 ) (OR 4 ) group, a —CN group, a group of formula (IIa), and a group of formula (IIIa):

A is a covalent bond, an oxygen atom or NH,

B is a covalent bond or NH,

m is 1, 2, 3, 4 or 5,

p is 1, 2 or 3,

Ra and Rb independently represent a hydrogen atom, a (C 1 -C 5 ) alkyl group or a (C 3 -C 6 ) cycloalkyl group,

Ra and Rb can further form together with the nitrogen atom to which they are attached a saturated 5- or 6-membered heterocycle optionally containing a further heteroatom chosen among N, O and S, said heterocycle being optionally substituted by one or more Ra, provided that when R′ is a group of formula (IIa) or a group of formula (IIIa), n′ may be 2 or 3 only if other R′ groups are different from said group of formula (IIa) or said group of formula (IIIa),

R″ is a hydrogen atom, a (C 1 -C 4 ) alkyl group or is a group of formula (IIa) as defined above,

the method comprising measuring the presence or level of expression of miR-124 in an eukaryotic cell from a biological sample, and comparing the presence or the level of expression of miR-124 to a control reference value,

wherein the control reference value is obtained from an isolated biological sample obtained from a patient suffering from an inflammatory disease and receiving a treatment, the efficacy of the treatment being to be determined or monitored, the isolated biological sample being taken from the patient before administration of the treatment.

9. The method according to claim 8 , wherein the biological sample is selected from a blood, a plasma, a serum, a saliva, an interstitial fluid, an urine sample, a cell sample, a cell culture, a cell line, a stem cell line, a Peripheral blood mononuclear cells (PBMC) containing sample, a tissue biopsy, an oral tissue, a gastrointestinal tissue, a skin, an oral mucosa sample, or a plurality of samples from a clinical trial, said sample being a crude sample or purified beforehand to various degrees prior to storage, processing, or measurement.

10. The method according to claim 1 , wherein the level of expression of miR-124 is assessed by using nucleic acid assays, nucleic acid arrays, Northern blots or PCR-based methods.

11. The method according to claim 8 , wherein the presence or level of expression of miR-124 is assessed by using nucleic acid assays, nucleic acid arrays, Northern blots or PCR-based methods.

12. The method according to claim 1 , wherein the level of expression of miR-124 is measured in step c) by performing a method for the detection and quantification of nucleic acids, which may be a hybridation-based method, said hybridation-based methods including PCR and quantitative-PCR (qRT-PCR or q-PCR) techniques or reverse transcriptase/polymerase based techniques.

13. The method according to claim 8 , wherein the presence or the level of expression of miR-124 is measured by performing a method for the detection and quantification of nucleic acids, which may be a hybridation-based method, said hybridation-based methods including PCR and quantitative-PCR (qRT-PCR or q-PCR) techniques or reverse transcriptase/polymerase based techniques.

14. The method according to claim 1 , further comprising a sequencing step.

15. The method according to claim 8 , further comprising a sequencing step.

16. The method according to claim 1 , wherein the measuring of the level of expression of miR-124 in step c) comprises (i) a step of extraction of cellular mRNAs, (ii) a step of reverse transcription of mRNA to DNA using a reverse transcriptase and (iii) a step of DNA amplification from DNA obtained on the previous step.

17. The method according to claim 8 , wherein the measuring of the presence or level of expression of miR-124 comprises (i) a step of extraction of cellular mRNAs, (ii) a step of reverse transcription of mRNA to DNA using a reverse transcriptase and (iii) a step of DNA amplification from DNA obtained on the previous step.

18. The method according to claim 1 , wherein a modulation of the level of expression of miR-124 relatively to a control reference value from a healthy donor, is indicative of the efficacy of the quinoline derivative for treating and/or preventing an inflammatory disease.

19. The method according to claim 8 , wherein an increased presence, or an increased level of expression, of miR-124 relative to the control reference value, is indicative of the efficacy of the compound of formula (I) for treating and/or preventing an inflammatory disease.

Priority Claims (1)

Continuity (4)

References Cited (302)